Myoclonus—characterized by sudden, brief, involuntary muscle jerks—is a common movement disorder feature in corticobasal syndrome (CBS). It serves as an important clinical sign that helps differentiate CBS from other atypical parkinsonian disorders and provides insight into the underlying neuroanatomical dysfunction. Myoclonus occurs in approximately 15-27% of CBS patients during their disease course[@caballol2019].
Clinical Presentation
Types of Myoclonus in CBS
Cortical Myoclonus
Most common type in CBS
Originates from dysfunction in the motor [cortex](/brain-regions/cortex)
Typically stimulus-sensitive (triggered by touch, sound, or visual stimuli)
Often affects distal muscles (fingers, hands)
Usually asymmetric, correlating with cortical pathology
Subcortical Myoclonus
Less common than cortical myoclonus
Originates from brainstem or spinal cord structures
Often generalized or axial in distribution
Myoclonus-Ataxia Syndrome
A subset of CBS patients present with myoclonus and cerebellar ataxia
May indicate additional cerebellar involvement
Can mimic other myoclonus disorders (e.g., opsoclonus-myoclonus)
Distribution and Pattern
...
Myoclonus in Corticobasal Syndrome
Overview
Myoclonus—characterized by sudden, brief, involuntary muscle jerks—is a common movement disorder feature in corticobasal syndrome (CBS). It serves as an important clinical sign that helps differentiate CBS from other atypical parkinsonian disorders and provides insight into the underlying neuroanatomical dysfunction. Myoclonus occurs in approximately 15-27% of CBS patients during their disease course[@caballol2019].
Clinical Presentation
Types of Myoclonus in CBS
Cortical Myoclonus
Most common type in CBS
Originates from dysfunction in the motor [cortex](/brain-regions/cortex)
Typically stimulus-sensitive (triggered by touch, sound, or visual stimuli)
Often affects distal muscles (fingers, hands)
Usually asymmetric, correlating with cortical pathology
Subcortical Myoclonus
Less common than cortical myoclonus
Originates from brainstem or spinal cord structures
Often generalized or axial in distribution
Myoclonus-Ataxia Syndrome
A subset of CBS patients present with myoclonus and cerebellar ataxia
May indicate additional cerebellar involvement
Can mimic other myoclonus disorders (e.g., opsoclonus-myoclonus)
Distribution and Pattern
Asymmetric: Reflects the characteristic asymmetric cortical involvement in CBS
Upper limb predominance: Hands and fingers most commonly affected
Focal to segmental: Typically remains localized but can progress
Action-exacerbated: Myoclonus often worsens with voluntary movement
May be superimposed with limb dystonia[@caballol2019]
Myoclonus-Dominant CBS Phenotype
A specific "myoclonus-predominant" phenotype has been described characterized by:[@caballol2019]
Prominent action myoclonus with voluntary movement
Often affecting upper limbs, sometimes superimposed with limb dystonia
Low-amplitude action myoclonus that may resemble action tremor
"Jerks contaminating all voluntary movements"
May have initially normal DaT-SPECT imaging, making diagnosis challenging
Prevalence
15-27% of CBS patients experience myoclonus during disease course
Cortical myoclonus accounts for approximately 70% of cases
More common than in PSP (where myoclonus is rare)
Less common than in Creutzfeldt-Jakob disease (where myoclonus occurs in >90%)
Myoclonus in CBS results from dysfunction in the cortical-subcortical motor networks:
Motor Cortex Dysfunction
[Tau](/proteins/tau) deposition in layer V pyramidal [neurons](/entities/neurons)
Reduced cortical inhibition
Hyperexcitability leading to myoclonic jerks
Thalamocortical Pathway Dysregulation
Abnormal thalamic output to motor cortex
Loss of inhibitory control
Disorganized motor neuron firing
Brainstem Involvement
Reticular formation dysfunction
Enhanced startle reflexes
Generalized myoclonus in severe cases
Mermaid diagram (expand to render)
Electrophysiological Findings
Surface EMG in CBS myoclonus shows:[@caballol2019]
Non-rhythmic, short-duration bursts (20-40 ms)
Silent periods appearing synchronously in muscles
Transcranial magnetic stimulation typically shows normal motor evoked potentials
Treatment
Pharmacological Management
First-Line Treatments
Levetiracetam
Dose: 500-1500mg twice daily
Efficacy: Variable response; may reduce myoclonus frequency
Clonazepam
Dose: 0.5-2mg daily (typically at bedtime)
Efficacy: First-line; may improve myoclonus and anxiety
Side effects: Sedation, dizziness
Valproic Acid
Dose: 500-1500mg daily
Monitoring: Liver function, platelets
Refractory Cases
Treatment of myoclonus in CBS is often challenging. The myoclonus-dominant phenotype has been reported to be refractory to multiple treatments including:[@caballol2019]
Levodopa (up to 1,250mg)
Levetiracetam
Clonazepam
For refractory cases, consider:
Combination therapy
Piracetam (2.4-4.8g daily)
Zonisamide (100-400mg daily)
5-Hydroxytryptophan (100-300mg daily)
Non-Pharmacological Management
Environmental safety: Padded helmets for fall protection
Adaptive equipment: Modified utensils, dressing aids
Occupational therapy: Safety assessments and compensatory strategies
Clinical Significance
Myoclonus in CBS has several clinical implications:
Diagnostic value: Helps distinguish CBS from PSP (where myoclonus is rare)
Phenotypic variation: May indicate a specific myoclonus-dominant subtype
Functional impact: Can significantly impair daily activities
Prognostic indicator: Refractory myoclonus may suggest more severe cortical involvement
Cross-Reference with PSP and FTD
CBS shares significant clinical and pathological overlap with other frontotemporal lobar degeneration (FTLD) spectrum disorders:
Progressive supranuclear palsy (PSP): While myoclonus is rare in PSP (<10%), cortical myoclonus can occur in PSP variants
Frontotemporal dementia (FTD): Myoclonus may occur in FTD, particularly in cases with motor features
Pick complex: The concept integrates FTD, CBS, and PSP as related conditions within the same neurodegenerative spectrum[@kertesz2003]
[Caballol et al., Movement Disorders Clinical Practice (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30637289/)
[Kertesz et al., Journal of Neural Transmission (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14629785/)
[Thompson et al., Journal of Neurology Neurosurgery and Psychiatry (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8891392/)
[Di Stasio et al., Journal of Neurology (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/30720235/)
[Unknown, Nouh & Younes, Current Treatment Options in Neurology (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/39886562/)
Pathway Diagram
The following diagram shows the key molecular relationships involving Myoclonus in Corticobasal Syndrome discovered through SciDEX knowledge graph analysis: